Gene
TMPRSS2
TMPRSS2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (13), Actionable biomarkers (2), Trial mentions (10), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention TMPRSS2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 21 of 11,460 | 0.18% |
| 2022 | 0 of 8,285 | 0.00% | 70 of 13,598 | 0.51% |
| 2021 | 2 of 8,692 | 0.02% | 111 of 15,045 | 0.74% |
| 2020 | 1 of 7,640 | 0.01% | 207 of 14,459 | 1.43% |
| 2019 | 1 of 7,300 | 0.01% | 12 of 12,159 | 0.10% |
| 2018 | 0 of 6,927 | 0.00% | 6 of 11,854 | 0.05% |
| 2017 | 0 of 6,558 | 0.00% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (13)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| LORGEN G.P. | Reagent supplier | Clinical validation | 1 | October 01, 2025 |
| Salus Discovery LLC | Diagnostic provider | Clinical validation | 1 | September 10, 2021 |
| Olympia Diagnostics, Inc. | Diagnostic provider | Clinical validationAnalytical validation | 2 | March 01, 2021 |
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | Date unknown |
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | Clinical validation | 1 | Date unknown |
Showing 5 of 13 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| TMPRSS2 fusion | Dna-pkc Inhibitors | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| TMPRSS2 fusion | Parp Inhibitors | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (10)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04769817 | Trial biospecimen (AACT) |
| NCT03784924 | Trial eligibility (AACT) |
| NCT05716425 | Trial eligibility (AACT) |
| NCT05057923 | Trial outcomes (AACT) |
| NCT04196803 | Trial outcomes (AACT) |
Showing 5 of 10 trial mentions.
Target-disease associations (315)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY sex reversal 11 | cardiovascular disease | Mouse knockout (IMPC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Acinar Prostate Adenocarcinoma, Foamy Gland Variant | cancer or benign tumor | Cancer Gene Census |
| Acinar Prostate Mucinous Adenocarcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 315 associations.
Vendor sourcing (45)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Alan Bryce | Trial sponsor | Mentioned in trial textTrial free-text mention | TMPRSS2 | View trial NCT04470544 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.842G>T (p.C281F) alteration is located in exon 9 (coding exon 9) of the TMPRSS2 gene. This alteration results from a G to T substitution at nucleotide ... | View ClinVar record SCV003577680.2 |
| Astellas Pharma US, Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | TMPRSS2 | View trial NCT02064582 |
| Beth Israel Deaconess Medical Center | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Inability to obtain blood and urine per SOP or conduct an attentive DRE * Unable to undergo/tolerate a prostate MRI or failure to conduct the MRI * Prio... | View trial NCT03784924 |
| Beth Israel Deaconess Medical Center | Trial collaborator | Mentioned in trial textTrial free-text mention | TMPRSS2 | View trial NCT03784924 |
Showing 5 of 45 sourcing records.
Trial-cited literature (546)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition. | The Journal of clinical investigation | 2025 | 5 |
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial. | Experimental hematology & oncology | 2025 | 2 |
| Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. | Nature medicine | 2024 | 24 |
| Neoantigens: promising targets for cancer therapy. | Signal transduction and targeted therapy | 2023 | 808 |
| Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). | eLife | 2023 | 187 |
Showing 5 of 546 papers.
Protein variant mentions (23)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A16V | 1 | 2023 | PMID 37466213 |
| p.A7R | 1 | 2021 | PMID 33961754 |
| p.D138Y | 1 | 2022 | PMID 35988541 |
| p.E354N | 1 | 2020 | PMID 32970989 |
| p.G181R | 1 | 2020 | PMID 32664879 |
Showing 5 of 23 variants.
Literature-extracted relations (77)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CURCUMIN | Chemical | negative_correlate |
Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions. | 2021 |
| .spironolactone | Chemical | negative_correlate |
COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. | 2021 |
| Propolis | Chemical | negative_correlate |
Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. | 2020 |
| Steroids | Chemical | negative_correlate |
The Resilient Child: Sex-Steroid Hormones and COVID-19 Incidence in Pediatric Patients. | 2020 |
| Hydroxychloroquine | Chemical | associate |
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. | 2020 |
Showing 5 of 77 relation assertions.
Organizations publishing (628)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 30 | 2012 to 2025 |
| Harvard Medical School | Academic | 23 | 2010 to 2021 |
| University of London | Academic | 21 | 2008 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 17 | 2009 to 2021 |
| University of California System | Academic | 13 | 2012 to 2022 |
Showing 5 of 628 organizations.
Where TMPRSS2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
280 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.